Yilu Liu

Dr. Yilu Liu

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
JZJinghan Zeng
Jinghan Zeng
YLYilu Liu
Yilu Liu
TZTianlang Zhao
Tianlang Zhao
JYJiansong Yuan
Jiansong Yuan
WYWeixian Yang
Weixian Yang
MWMan Wang
Man Wang
Objective: We aimed to conduct a meta-analysis of treatments for large vessel coronary artery disease between drug-coated balloons and drug-eluting stents. Method: We searched databases including PubMed, Web of Science, Cochrane, CNKI, and Wanfang, and selected randomized controlled trials (RCTs) or cohort studies which compared drug-coated balloons (DCBs) with drug-eluting stents (DESs). The reference vessel diameter (RVD) should be greater than 2.75 mm. The results of 12 studies with a total of 2634 patients were included in this meta-analysis. Results: The results showed that the DCB group was not inferior to the DES group in terms of the incidence of target lesion revascularization (TLR). (RR = 1.25, 95% CI: [0.84, 1.85], p = 0.27, I2 = 0%), and the incidence of bleeding events in the DCB group was lower than that in the DES group (RR = 0.30, 95% CI: [0.15, 0.59], p = 0.0004). The results also showed that the post-intervention minimal lumen diameter (MLD) in the DCB group was smaller than that in the DES group. (RR = −0.37, 95% CI: [−0.59, −0.16], p = 0.0007), but the follow-up MLD in the DCB group was not less than that in the DES group (RR = −0.03, 95% CI: [−0.14,−0.08], p = 0.61). Additionally the DCB group had less late lumen loss (LLL) compared with the DES group. (RR = −0.31, 95% CI: [−0.60, −0.02], p < 0.0001). Conclusion: This meta-analysis confirms that in the early and late stages after percutaneous coronary intervention (PCI), DCB is not inferior in efficacy and safety to DES for de novo large coronary lesions with RVD > 2.75 mm.

1 January 2026 in Journal of Diabetes Research
Verified
Journal Article
Open access
PDF file
YLYilu Liu
Yilu Liu
YZYingxuan Zhu
Yingxuan Zhu
JYJiansong Yuan
Jiansong Yuan
LLLili Liu
Lili Liu
DZDingyue Zhang
Dingyue Zhang
WYWeixian Yang
Weixian Yang
Objective: Individuals with both diabetes and hypertension face a heightened risk of all‐cause death. We aimed to validate the DHAM score′s performance in predicting 5‐year overall mortality in two prospective cohorts. Methods: The internal validation cohort comprised 3291 patients with diabetes and hypertension drawn from the 1999–2014 cycles of the National Health and Nutrition Examination Survey database. The external validation cohort comprised 2478 patients from the 2008–2015 China Kailuan cohort. The DHAM score was constructed from eight predictors (age, sex, education, marriage, smoking, cardiovascular disease, serum albumin, and urea nitrogen). Renal dysfunction was determined by an estimated glomerular filtration rate < 60 mL/min/1.73 m 2 computed via the Chronic Kidney Disease Epidemiology Collaboration equation. Results: The C‐index was 0.758 (95% CI: 0.743–0.833) in the NHANES database and 0.741 (95% CI: 0.731–0.790) in the Kailuan cohort. A DHAM score > 148 independently predicted 5‐year all‐cause death in NHANES (adjusted‐HR 10.03, 95% CI: 3.37–18.83, p < 0.001); after recalibration, a score > 152 independently predicted mortality in Kailuan (adjusted‐HR 9.24, 95% CI: 4.71–16.84, p < 0.001). The patients were further stratified by DHAM score and renal function into three risk groups. Intermediate‐ and high‐risk categories showed higher 5‐year all‐cause death rates than low‐risk categories across both cohorts (log‐rank p < 0.001). Conclusion: The DHAM score had a robust prognostic value for 5‐year all‐cause death among individuals with both diabetes and hypertension. Higher DHAM score combined with renal dysfunction could identify patients at highest risk of all‐cause death. Trial Registration: Chinese Registry of Clinical Trials: ChiCTR2000029767